4892 — Cyfuse Biomedical KK Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Cyfuse Biomedical KK, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 708 | 374 | 61.1 | 54.4 | 231 |
| Cost of Revenue | |||||
| Gross Profit | 571 | 241 | 37.7 | 16.9 | 114 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 638 | 838 | 759 | 951 | 1,059 |
| Operating Profit | 70.6 | -464 | -697 | -896 | -828 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 145 | -472 | -586 | -870 | -761 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 143 | -474 | -589 | -872 | -764 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 143 | -474 | -589 | -872 | -764 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 143 | -474 | -589 | -872 | -764 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 19.9 | -57.7 | -75.4 | -108 | -86.8 |
| Dividends per Share |